To delineate the immune context of LLT1TC high patients, we evaluated the distribution of CD4+ T cells, CD8+ T cells, Foxp3+ Tregs, CD68+ tumor‐associated macrophages, and CD19+ B cells (Figure 3A). This evidence concerns the gene CD19 and neoplasm.